Related references
Note: Only part of the references are listed.Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study
Emmanuel S. Antonarakis et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Pembrolizumab for advanced anal squamous cell carcinoma (ASCC): Results from the multicohort, phase II KEYNOTE-158 study
Aurelien Marabelle et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Mismatch repair deficiency in metastatic prostate cancer: Response to PD-1 blockade and standard therapies
Laura S. Graham et al.
PLOS ONE (2020)
Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant Prostate Cancer: Preliminary Analysis of Patients in the CheckMate 650 Trial
Padmanee Sharma et al.
CANCER CELL (2020)
IMbassador250: A phase III trial comparing atezolizumab with enzalutamide vs enzalutamide alone in patients with metastatic castration-resistant prostate cancer (mCRPC)
Christopher J. Sweeney et al.
CANCER RESEARCH (2020)
Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study
Aurelien Marabelle et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
The tumor immune microenvironment differs between metastatic castrate resistant prostate cancer (CRPC) and hormone sensitive prostate cancer (HSPC).
Kobe Chi Yung Yuen et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial
Brian I. Rini et al.
LANCET (2019)
Pembrolizumab in men with heavily treated metastatic castrate-resistant prostate cancer
Matthew D. Tucker et al.
CANCER MEDICINE (2019)
Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer
Ronald de Wit et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade
Wassim Abida et al.
JAMA ONCOLOGY (2019)
Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study
A. R. Hansen et al.
ANNALS OF ONCOLOGY (2018)
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
Julie R. Brahmer et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
David F. McDermott et al.
NATURE MEDICINE (2018)
Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer
Karim Boudadi et al.
Oncotarget (2018)
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
L. Horn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
P. Schmid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations
Fatima Karzai et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
Achim Rittmeyer et al.
LANCET (2017)
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Dung T. Le et al.
SCIENCE (2017)
Comprehensive immunohistochemical analysis of PD-L1 shows scarce expression in castration-resistant prostate cancer
Christian D. Fankhauser et al.
Oncotarget (2017)
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
Howard I. Scher et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
Louis Fehrenbacher et al.
LANCET (2016)
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
Jonathan E. Rosenberg et al.
LANCET (2016)
PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
Weiping Zou et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer
Julie N. Graff et al.
ONCOTARGET (2016)
Antitumor vaccination of prostate cancer patients elicits PD-1/PD-L1 regulated antigen-specific immune responses
Brian T. Rekoske et al.
ONCOIMMUNOLOGY (2016)
The third line of treatment for metastatic prostate cancer patients: Option or strategy?
Giandomenico Roviello et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2015)
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
Charles J. Ryan et al.
LANCET ONCOLOGY (2015)
PD-L1 is highly expressed in Enzalutamide resistant prostate cancer
Jennifer L. Bishop et al.
ONCOTARGET (2015)
Immunotherapy for prostate cancer: recent developments and future challenges
Michael T. Schweizer et al.
CANCER AND METASTASIS REVIEWS (2014)
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Roy S. Herbst et al.
NATURE (2014)
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy REPLY
Tomasz M. Beer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
T. M. Beer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Oncology Meets Immunology: The Cancer-Immunity Cycle
Daniel S. Chen et al.
IMMUNITY (2013)
Molecular Pathways: Next-Generation Immunotherapy-Inhibiting Programmed Death-Ligand 1 and Programmed Death-1
Daniel S. Chen et al.
CLINICAL CANCER RESEARCH (2012)
Characterising the castration-resistant prostate cancer population: a systematic review
M. Kirby et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2011)
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer.
Philip W. Kantoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the prostate cancer clinical trials working group
Howard I. Scher et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)